Ovarian cancer: Current status and strategies for improving therapeutic outcomes
Of all the gynecologic tumors, ovarian cancer (OC) is known to be the deadliest. Advanced‐
stages of OC are linked with high morbidity and low survival rates despite the immense …
stages of OC are linked with high morbidity and low survival rates despite the immense …
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with
an aggressive disease course despite currently approved therapeutics. The recent …
an aggressive disease course despite currently approved therapeutics. The recent …
Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer
Ionizing radiation causes DNA damage and is a mainstay for cancer treatment, but
understanding of its genomic impact is limited. We analyzed mutational spectra following …
understanding of its genomic impact is limited. We analyzed mutational spectra following …
British Gynaecological Cancer Society (BGCS) uterine cancer guidelines: Recommendations for practice
J Morrison, J Balega, L Buckley, A Clamp… - European Journal of …, 2022 - Elsevier
The remit of this guideline is to collate and propose evidence-based guidelines for the
diagnosis and management of uterine cancer. This document covers all uterine cancers of …
diagnosis and management of uterine cancer. This document covers all uterine cancers of …
PARP inhibitors in ovarian cancer
G Mittica, E Ghisoni, G Giannone… - Recent patents on …, 2018 - ingentaconnect.com
Background: Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery
and platinum doublet chemotherapy, is associated with high risk of relapse and poor …
and platinum doublet chemotherapy, is associated with high risk of relapse and poor …
[HTML][HTML] Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic
C Winter, MP Nilsson, E Olsson, AM George, Y Chen… - Annals of …, 2016 - Elsevier
Background A mutation found in the BRCA1 or BRCA2 gene of a breast tumor could be
either germline or somatically acquired. The prevalence of somatic BRCA1/2 mutations and …
either germline or somatically acquired. The prevalence of somatic BRCA1/2 mutations and …
The potential of PARP inhibitors in targeted cancer therapy and immunotherapy
J Hunia, K Gawalski, A Szredzka… - Frontiers in molecular …, 2022 - frontiersin.org
DNA damage response (DDR) deficiencies result in genome instability, which is one of the
hallmarks of cancer. Poly (ADP-ribose) polymerase (PARP) enzymes take part in various …
hallmarks of cancer. Poly (ADP-ribose) polymerase (PARP) enzymes take part in various …
Current status of poly (ADP-ribose) polymerase inhibitors and future directions
A Ohmoto, S Yachida - OncoTargets and therapy, 2017 - Taylor & Francis
Inhibitors of poly (ADP-ribose) polymerases (PARPs), which play a key role in DNA
damage/repair pathways, have been developed as antitumor agents based on the concept …
damage/repair pathways, have been developed as antitumor agents based on the concept …
Peptide-mediated delivery of therapeutic mRNA in ovarian cancer
D van den Brand, MAJ Gorris, AH van Asbeck… - European Journal of …, 2019 - Elsevier
Ovarian cancer is the most lethal gynecological malignancy in the developed world. In spite
of intensive research, the mortality has hardly decreased over the past twenty years. This …
of intensive research, the mortality has hardly decreased over the past twenty years. This …
British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice
Epithelial ovarian cancer (EOC) is the 6th most common cancer among women in the UK
(2014) and accounts for 4% of all new cases of cancer in females: it has the highest mortality …
(2014) and accounts for 4% of all new cases of cancer in females: it has the highest mortality …